<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/37DE1B14-06DD-4E06-AAC5-56F5BBED7FFF"><gtr:id>37DE1B14-06DD-4E06-AAC5-56F5BBED7FFF</gtr:id><gtr:name>MRC Toxicology Unit</gtr:name><gtr:address><gtr:line1>Hodgkin Building</gtr:line1><gtr:line2>University of Leicester</gtr:line2><gtr:line3>PO Box 138,  Lancaster Road</gtr:line3><gtr:line4>Leicester</gtr:line4><gtr:postCode>LE1 9HN</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37DE1B14-06DD-4E06-AAC5-56F5BBED7FFF"><gtr:id>37DE1B14-06DD-4E06-AAC5-56F5BBED7FFF</gtr:id><gtr:name>MRC Toxicology Unit</gtr:name><gtr:address><gtr:line1>Hodgkin Building</gtr:line1><gtr:line2>University of Leicester</gtr:line2><gtr:line3>PO Box 138,  Lancaster Road</gtr:line3><gtr:line4>Leicester</gtr:line4><gtr:postCode>LE1 9HN</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/CBC53B60-9233-400B-9E75-D6156F3A5988"><gtr:id>CBC53B60-9233-400B-9E75-D6156F3A5988</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:surname>Dyer</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U132670597"><gtr:id>DE6AA0C3-3992-401E-9F42-DBCF01D18E80</gtr:id><gtr:title>Genomic Instability in mature B-cells</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U132670597</gtr:grantReference><gtr:abstractText>The lymphomas and leukaemias together comprise the fourth most common form of malignancy in man. Fifty years ago, these diseases were inevitably fatal. Although our ability to cure some with combination chemotherapy is a triumph of 20th century empirical medicine, many remain incurable and for the elderly, such approaches may not be appropriate. Therapy targeting the tumours specifically remains a significant unmet need.||Our group is investigating two aspects of these diseases. Firstly, we are seeking to understand how such malignancies arise, using a molecular cytogenetic-lead approach to define genetic changes within the malignant cells. Analysis of the genes targeted to the immunoglobulin loci by chromosomal translocations will not only identify pathogenetic mechanisms, but will allow new diagnostic and possibly therapeutic approaches. Secondly, in collaboration with Professor Cohen and Dr. MacFarlane and with other academic and industrial collaborations, we are seeking to define optimal conditions for targeted therapy using novel monoclonal antibodies and TRAIL ligands.||Using proteomic approaches, we have defined a number of B-cell specific cell surface molecules of unknown function, to which we will generate MAbs and ScFv reagents.||We shall continue to assess new MAbs clinically in patients with lymphoid malignancies. Chronic lymphocytic leukaemia provides an excellent experimental model for the assessment of new therapies since efficacy can be assessed simply by monitoring the peripheral blood.</gtr:abstractText><gtr:technicalSummary>Several forms of cancer are linked to gross chromosomal abnormalities, which result from a general instability of the genome. Genome instability can be caused by exposure to toxic chemicals or by other genotoxic or epigenetic factors. In the pathogenesis of the malignancies of mature lymphocytes, namely the non-Hodgkin lymphomas and chronic lymphocytic leukaemia, chromosomal translocations involving the immunoglobulin loci are common and we have developed techniques to facilitate their cloning.||In collaboration with several groups worldwide, we continue to clone new chromosomal translocations, since although rare, these allow identification of genes that play a pivotal role in the development of normal and malignant B-cells.||Work in the lab is now establishing how the involved oncogenes transform mature B-cells. However, we are also using whole cell genomic and proteomic approaches to search for additional abnormalities, including the identification of novel tumour suppressor genes.||Since, the pathogenesis of these diseases is not known and many remain incurable with conventional chemotherapy, the molecular dissection of the genetic defects associated with these malignancies should allow rational development of new and effective targeted therapies. Our studies provide new insights in the mechanisms of development of cancer and at the same time provide new targets for the development of safe drugs.</gtr:technicalSummary><gtr:fund><gtr:end>2014-02-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2002-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>3994234</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>National Lymphoma Association Patient Update Day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B36371C0-0286-4524-9642-8F4A6D353C85</gtr:id><gtr:impact>Meeting attended by some 250 lymphoma patients and their carers. Outlined developments in targeted therapy of B-cell malignancies.

Patients attending my clinics from outside Leicester!!</gtr:impact><gtr:outcomeId>gGtjRquQ4Sg</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Chronic lymphocytic leukaemia support association</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>83C5F1F3-70C6-4AA9-8162-C3090F0453E0</gtr:id><gtr:impact>Meetings attended by about 50-100 patients with CLL and their carers

referred patients from outside region</gtr:impact><gtr:outcomeId>rQ2Ta9RdqEL</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CLL Masterclasses</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F59DD916-3F96-4162-8EC2-A1655D40DC75</gtr:id><gtr:impact>Two day educational sessions held in Leicester for clinicians, pharmacists, nurses to be updated on CLL in general and in particular on the work ongoing in Leicester. Four meetings over the past two years.

Raises profile of the group within UK and internationally.</gtr:impact><gtr:outcomeId>D032537A308</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public lectures on advances in genetics GENIE (Genetics Education Networking for Innovation and Excellence)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>F3002F9C-185D-4709-B895-7454EC6D7C51</gtr:id><gtr:impact>Dr Aneela Majid in my group recently helped to establish a new series of public engagement lectures (the first of which was very successful and received lots of positive feedback) and is also the co-editor of GENIE News, the Centre's Newsletter.

Public engagement with advances in medical genetics.</gtr:impact><gtr:outcomeId>fSTRbu7sgZg</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CLL update</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5931197A-5095-44AB-A727-5E0FF2E5429C</gtr:id><gtr:impact>Host annual meeting in Leicester on B-cell malignancies and specifically CLL

Raising profile.</gtr:impact><gtr:outcomeId>A9498831C18</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>215000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Hope Foundation for Cancer Research (Rutland and Leicestershire)</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>Hope Against Cancer (Rutland and Leicestershire)</gtr:fundingOrg><gtr:id>5D1B4FCA-59C6-44CC-AF9D-496B756D2E40</gtr:id><gtr:outcomeId>98337EA65CB0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>90000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRCT development gap funding</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>MRC Technology (MRCT)</gtr:fundingOrg><gtr:id>2BB29F54-75B7-4255-A3A3-823E43F7BB49</gtr:id><gtr:outcomeId>ic19FLujNkD0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>27000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University of Leicester Centre for Translational studies/University of Leicester</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>University of Leicester</gtr:fundingOrg><gtr:id>D147F856-3E5D-4697-9CB7-AC501FC838FC</gtr:id><gtr:outcomeId>UjebBeanPv10</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>130000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Leukaemia Research funding (Modulation of apoptosis for leukemia therapy)</gtr:description><gtr:end>2011-05-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>B6ADA58D-6FE0-415F-AB57-507E3FA1E2AC</gtr:id><gtr:outcomeId>3FFC10BB0A30</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>Identification of potential new therapeutic targets expressed on the cell surface of B-cell malignancies through 
a) Proteomic analysis of the cell surface membrane. This study lead to the identification of HVCN1. 
b) Molecular cloning of novel chromosomal translocation breakpoints. CRLF2 was identified as a recurrent target of chromosomal translocations and has been validated as a therapeutic target.</gtr:description><gtr:id>D99E6748-0CEE-4CBB-A061-18BE1D852899</gtr:id><gtr:impact>Currently developing potential therapeutic antibodies to CRLF2 with MRCT. HVCN1 as a possible therapeutic target.</gtr:impact><gtr:outcomeId>97853F36688</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>New target identification for B-cell malignancies</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2008</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Antibodies produced in collaboration with MRCT and with Genzyme. More recently antibody-drug conjugates made in collaboration with ADC Biotech</gtr:description><gtr:id>A774ECB8-6238-430B-8FA6-DF41B74A38A2</gtr:id><gtr:impact>Nil as yet - antibodies being assessed for activity just now</gtr:impact><gtr:outcomeId>ZzZcJq7c9n6</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>CRLF2 antibodies</gtr:title><gtr:type>Antibody</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Comprehensive population-based database of patients with B-cell malignancies in Leicester. Full molecular classification of malignancies is married with demographic and clinical details. This is a unique and powerful resource as population-based. It has resulted in multiple publications, two of which appended here.</gtr:description><gtr:id>30A16C09-F960-4C1E-8A7B-13E4537C5DAD</gtr:id><gtr:impact>We are currently mining data from this collection to determine for example responses to standard chemotherapy on a population-basis - responses appear to be much shorter in some instances from data derived from clinical trials.</gtr:impact><gtr:outcomeId>553D468E97B</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Database of B-cell malignancy</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>583A249C-E85C-41CF-A607-68B2E7D7089E</gtr:id><gtr:title>Barriers to effective TRAIL-targeted therapy of malignancy.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50211a37a4654b2dfd8ff8b075e17c3a"><gtr:id>50211a37a4654b2dfd8ff8b075e17c3a</gtr:id><gtr:otherNames>Dyer MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>3EB4500FCEF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2B34422-BDD8-4374-920D-D978182DC2A4</gtr:id><gtr:title>Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/09b1298cf346413816e3a24b41021b8c"><gtr:id>09b1298cf346413816e3a24b41021b8c</gtr:id><gtr:otherNames>Baou M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>nkp9rXzq762</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5546BD4E-9327-45ED-976F-7F5F5992BAB3</gtr:id><gtr:title>Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9b99469952c8d3f6e301023ab6fd7e1"><gtr:id>b9b99469952c8d3f6e301023ab6fd7e1</gtr:id><gtr:otherNames>Walter HS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5aa41c26b04952.44727913</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0EB973C-423C-4295-B1C2-EEF68469B408</gtr:id><gtr:title>The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein.</gtr:title><gtr:parentPublicationTitle>Biochemical and biophysical research communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a805d21d2fdc8cd924744bf32f7e6da"><gtr:id>2a805d21d2fdc8cd924744bf32f7e6da</gtr:id><gtr:otherNames>Vogler M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-291X</gtr:issn><gtr:outcomeId>erVSYP5tcH7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0BC6C09-0655-4B29-A526-AEA67406798E</gtr:id><gtr:title>Dopamine targets cycling B cells independent of receptors/transporter for oxidative attack: Implications for non-Hodgkin's lymphoma.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5a989293a1b4a2e9876ac67ca1915ab"><gtr:id>c5a989293a1b4a2e9876ac67ca1915ab</gtr:id><gtr:otherNames>Meredith EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>F0D305D8952</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EDBF4F6E-2027-45E6-9C8B-07ED02A0FFC3</gtr:id><gtr:title>Different forms of cell death induced by putative BCL2 inhibitors.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a805d21d2fdc8cd924744bf32f7e6da"><gtr:id>2a805d21d2fdc8cd924744bf32f7e6da</gtr:id><gtr:otherNames>Vogler M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>02DBA183F21</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C005197-62FA-4404-8027-E2859DFFBF99</gtr:id><gtr:title>The BCL11AXL transcription factor: its distribution in normal and malignant tissues and use as a marker for plasmacytoid dendritic cells.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/23668fcd4d039e751b62526d84e68aa5"><gtr:id>23668fcd4d039e751b62526d84e68aa5</gtr:id><gtr:otherNames>Pulford K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>410031F28DF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>109E3F9B-13EB-4FF1-86AE-87FD9F038B03</gtr:id><gtr:title>Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbae276620dcaf849fe6b412ea6dc442"><gtr:id>fbae276620dcaf849fe6b412ea6dc442</gtr:id><gtr:otherNames>Robles EF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58c798526152e5.85342952</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF9D6B85-35BC-4C76-A279-72334867B4E4</gtr:id><gtr:title>Bcl-2 inhibitors: small molecules with a big impact on cancer therapy.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a805d21d2fdc8cd924744bf32f7e6da"><gtr:id>2a805d21d2fdc8cd924744bf32f7e6da</gtr:id><gtr:otherNames>Vogler M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>35B26327E0E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FEFCF999-671E-4002-9F26-3AEA976E3F8B</gtr:id><gtr:title>Trisomy 19 is associated with trisomy 12 and mutated IGHV genes in B-chronic lymphocytic leukaemia.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b92c3da1f3a0202772ef3197aabac7cd"><gtr:id>b92c3da1f3a0202772ef3197aabac7cd</gtr:id><gtr:otherNames>Sellmann L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>63342B95146</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A2BDAFC-2DBC-4A5E-8916-97D028FDCA68</gtr:id><gtr:title>TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a7646eb6d6d6dc2890439db5ed02c07"><gtr:id>4a7646eb6d6d6dc2890439db5ed02c07</gtr:id><gtr:otherNames>Natoni A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>DE8F9A6F667</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A85A1DE1-C635-436C-A32B-F16082CACC46</gtr:id><gtr:title>Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma.</gtr:title><gtr:parentPublicationTitle>Molecular &amp; cellular proteomics : MCP</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/398a9184d82432ea64cdc3932cb993ea"><gtr:id>398a9184d82432ea64cdc3932cb993ea</gtr:id><gtr:otherNames>Boyd RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1535-9476</gtr:issn><gtr:outcomeId>E0E40DC364E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED8B5AAC-8CAF-4F7F-868C-3A3754B98644</gtr:id><gtr:title>Pyoderma gangrenosum complicating pegylated granulocyte colony-stimulating factor in Hodgkin lymphoma.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e8757c78aced72803a28c9d9735315f"><gtr:id>9e8757c78aced72803a28c9d9735315f</gtr:id><gtr:otherNames>Miall FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>B308D3D3A2F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>289E6832-5DA7-4A6A-A63B-556DF7CEB929</gtr:id><gtr:title>A ribosome-related signature in peripheral blood CLL B cells is linked to reduced survival following treatment.</gtr:title><gtr:parentPublicationTitle>Cell death &amp; disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d276175cd6d2fe457c788daaa44c255"><gtr:id>6d276175cd6d2fe457c788daaa44c255</gtr:id><gtr:otherNames>Sbarrato T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58c7987823e3b9.66218339</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>897F78FB-CEB3-4678-903E-2F615DC6849E</gtr:id><gtr:title>Primary lymphoma-like lesions of the uterine cervix; sheep in wolves' clothing.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50211a37a4654b2dfd8ff8b075e17c3a"><gtr:id>50211a37a4654b2dfd8ff8b075e17c3a</gtr:id><gtr:otherNames>Dyer MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>hjxvWWhiUMs</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>062CBFCE-327C-47F9-A9BA-CB34098DF3EC</gtr:id><gtr:title>Positron emission tomography features of hidradenitis suppurativa.</gtr:title><gtr:parentPublicationTitle>The British journal of radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8ef9035afb86bda1b2ef3a8387a2d7d"><gtr:id>f8ef9035afb86bda1b2ef3a8387a2d7d</gtr:id><gtr:otherNames>Simpson RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-1285</gtr:issn><gtr:outcomeId>X84cGHwf8MC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86031512-8BDC-4AC7-9A22-24F6584BAD5C</gtr:id><gtr:title>BCL2 expression in chronic lymphocytic leukemia: lack of association with the BCL2 938A&amp;gt;C promoter single nucleotide polymorphism.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e6a552e5d5bb32456180c5d8cc7ff7e"><gtr:id>2e6a552e5d5bb32456180c5d8cc7ff7e</gtr:id><gtr:otherNames>Majid A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>8D40C6E0010</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA3DE141-7BED-419B-9964-C327E828B6B0</gtr:id><gtr:title>Drug cross-resistance and therapy-induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b097e1d9592a8e30cdc32f4c090e6b58"><gtr:id>b097e1d9592a8e30cdc32f4c090e6b58</gtr:id><gtr:otherNames>Bosanquet AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>3D9EB56FAFB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11AD2FDC-1A88-4609-BEAA-5E79A99E309E</gtr:id><gtr:title>Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with high density single nucleotide polymorphism arrays identifies novel common genomic lesions and acquired uniparental disomy.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea76032ddb50dce7fc19f7d1835db8a9"><gtr:id>ea76032ddb50dce7fc19f7d1835db8a9</gtr:id><gtr:otherNames>Nowak D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>F646633E971</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BCF6C1C5-2C55-462E-9C52-43D049F650FA</gtr:id><gtr:title>Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33eb8a5e9fc139b71ff50a31a8e51f6a"><gtr:id>33eb8a5e9fc139b71ff50a31a8e51f6a</gtr:id><gtr:otherNames>Grigg A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>58c797364d7618.26871395</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C74419B1-9573-43D7-8EA7-313992E74107</gtr:id><gtr:title>Caspase cleavage of Itch in chronic lymphocytic leukemia cells.</gtr:title><gtr:parentPublicationTitle>Biochemical and biophysical research communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5ee5a13f7d6b0787d4919dd19ba893a"><gtr:id>c5ee5a13f7d6b0787d4919dd19ba893a</gtr:id><gtr:otherNames>Rossi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-291X</gtr:issn><gtr:outcomeId>771878C4163</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>827F38BE-AF9A-4F73-BAF8-47A8D8F76DBE</gtr:id><gtr:title>David Galton--the thesis years.</gtr:title><gtr:parentPublicationTitle>Leukemia &amp; lymphoma</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b4a923ef8dd82b90f9a5710a8e87cc2"><gtr:id>2b4a923ef8dd82b90f9a5710a8e87cc2</gtr:id><gtr:otherNames>Dyer M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1026-8022</gtr:issn><gtr:outcomeId>FA56352D463</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF4A594B-FEF8-4625-8747-5E78F77DCC13</gtr:id><gtr:title>Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75863d44d38390b793a438ac87b9f44b"><gtr:id>75863d44d38390b793a438ac87b9f44b</gtr:id><gtr:otherNames>Inoue S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn><gtr:outcomeId>C22678FC92D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D5D17FD-6391-4B1A-8609-E608E7A3AA37</gtr:id><gtr:title>Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87679e9fb84b0062da081b38f62af641"><gtr:id>87679e9fb84b0062da081b38f62af641</gtr:id><gtr:otherNames>M?ssner E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>T5qxDshpo2Q</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6064939C-FD46-47DB-801F-F6B2B1826F08</gtr:id><gtr:title>Proteomic analysis of B-cell malignancies.</gtr:title><gtr:parentPublicationTitle>Journal of proteomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/398a9184d82432ea64cdc3932cb993ea"><gtr:id>398a9184d82432ea64cdc3932cb993ea</gtr:id><gtr:otherNames>Boyd RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1874-3919</gtr:issn><gtr:outcomeId>V8Muz4VGNnv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B25AFE0D-E90E-4CB6-8D17-E113F58302E7</gtr:id><gtr:title>Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75863d44d38390b793a438ac87b9f44b"><gtr:id>75863d44d38390b793a438ac87b9f44b</gtr:id><gtr:otherNames>Inoue S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>04BB18BDF15</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC817BDC-CA2E-403F-995A-327C8785B61D</gtr:id><gtr:title>Biallelic inactivation of TRAF3 in a subset of B-cell lymphomas with interstitial del(14)(q24.1q32.33).</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/975a5f7128d7e2300880c46017366ddd"><gtr:id>975a5f7128d7e2300880c46017366ddd</gtr:id><gtr:otherNames>Nagel I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>7E11CED6B57</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9A18C09-E4CE-43C7-8125-A56207ECE836</gtr:id><gtr:title>Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/196802475597e2548b1d47d8f1c9b107"><gtr:id>196802475597e2548b1d47d8f1c9b107</gtr:id><gtr:otherNames>Cario G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>M15Zykd2RZH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7EC1F1B8-E524-452A-827A-D1931C4548AE</gtr:id><gtr:title>The SWI/SNF subunit Bcl7a contributes to motor coordination and Purkinje cell function.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b733b996b685ac527f3b6b157c10d39"><gtr:id>0b733b996b685ac527f3b6b157c10d39</gtr:id><gtr:otherNames>Wischhof L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5aa419b9d7f7a7.74920870</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A40B9609-47F6-4550-B813-B4C6DA89C445</gtr:id><gtr:title>Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a3eeb80fc28b775b95293b075a1afe4"><gtr:id>7a3eeb80fc28b775b95293b075a1afe4</gtr:id><gtr:otherNames>Mestre-Escorihuela C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>A8EAC0DBB91</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>928C83EB-30C0-4A3A-867F-1C1D2199DFDB</gtr:id><gtr:title>A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed6f9da3730a406e646b47fd83fc1396"><gtr:id>ed6f9da3730a406e646b47fd83fc1396</gtr:id><gtr:otherNames>Pratt G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>5aa41b5aeaeb35.85454995</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CF231F7-4495-4DF4-866C-8FBAC4FB8EA4</gtr:id><gtr:title>Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8738b2c5c5373a5b37b8af22b5eaa1f0"><gtr:id>8738b2c5c5373a5b37b8af22b5eaa1f0</gtr:id><gtr:otherNames>Morschhauser F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>04A7956960E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF7B3CE6-579E-4FF0-A449-0A4DEE6BDEC5</gtr:id><gtr:title>A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4b5d84f652c31eda62fe303f373718be"><gtr:id>4b5d84f652c31eda62fe303f373718be</gtr:id><gtr:otherNames>Di Bernardo MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>8A90B966919</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11058D06-42D7-4A42-AE11-26E84419E07F</gtr:id><gtr:title>Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL).</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f180a0b54bcb9151e6c8386003d17dd9"><gtr:id>f180a0b54bcb9151e6c8386003d17dd9</gtr:id><gtr:otherNames>Betticher DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn><gtr:outcomeId>641F3226174</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4DAB0B2E-F223-47B4-96E4-CFC974043A9B</gtr:id><gtr:title>TP53 codon 72 polymorphism in patients with chronic lymphocytic leukaemia: identification of a subgroup with mutated IGHV genes and poor clinical outcome.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e6a552e5d5bb32456180c5d8cc7ff7e"><gtr:id>2e6a552e5d5bb32456180c5d8cc7ff7e</gtr:id><gtr:otherNames>Majid A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>PL31agm4NL5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>130C0635-C75A-4D18-ADCA-B5E67A0A5B73</gtr:id><gtr:title>Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5305ca8144c598afe93bfa8d60948b33"><gtr:id>5305ca8144c598afe93bfa8d60948b33</gtr:id><gtr:otherNames>Johnson NA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>043833B5BCC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CCD65082-5909-41EA-AA9B-9DA5DBD08E10</gtr:id><gtr:title>Hsp72 and Nek6 Cooperate to Cluster Amplified Centrosomes in Cancer Cells.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40f1d465355d50f007c6f616a04e3273"><gtr:id>40f1d465355d50f007c6f616a04e3273</gtr:id><gtr:otherNames>Sampson J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>5aa41b30384825.50275842</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6151D8E5-D50F-49B2-BD96-5AC2DB5F91F0</gtr:id><gtr:title>Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c8b2715d1c16f9b9d1f3591c107b062f"><gtr:id>c8b2715d1c16f9b9d1f3591c107b062f</gtr:id><gtr:otherNames>Russell LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>EAC5FCFADC4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F612064-7694-4424-8CF2-004C277518FF</gtr:id><gtr:title>Voltage-gated proton channels maintain pH in human neutrophils during phagocytosis.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe4d7da3b7efbd3f7b838fe8b1e14df3"><gtr:id>fe4d7da3b7efbd3f7b838fe8b1e14df3</gtr:id><gtr:otherNames>Morgan D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>1FDD0CEFC7A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E834120-A08A-4F5C-B3D8-D3AD154B896C</gtr:id><gtr:title>p73, miR106b, miR34a, and Itch in chronic lymphocytic leukemia.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/247414815407f8c50511cf613d791a43"><gtr:id>247414815407f8c50511cf613d791a43</gtr:id><gtr:otherNames>Rivetti di Val Cervo P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>1975365B0DC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C522AAD-CEA4-4895-A8E5-CB1919B51FA1</gtr:id><gtr:title>Paradoxical activation of alternative pro-survival pathways determines resistance to MEK inhibitors in chronic lymphocytic leukaemia.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aabb4a3c08d22654d635504cdccd286f"><gtr:id>aabb4a3c08d22654d635504cdccd286f</gtr:id><gtr:otherNames>Chen Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>5aa41b09752296.66267714</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C7CCF5A-558E-4D36-B315-94C237F215B1</gtr:id><gtr:title>Deregulation of the telomerase reverse transcriptase (TERT) gene by chromosomal translocations in B-cell malignancies.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/975a5f7128d7e2300880c46017366ddd"><gtr:id>975a5f7128d7e2300880c46017366ddd</gtr:id><gtr:otherNames>Nagel I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>KeqvUqSUwPN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA1E1A96-C53E-42CD-8A43-18CF5BCECAF9</gtr:id><gtr:title>Bilateral subdural hygromas following intrathecal methotrexate.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b8ec340d2699a7f67d03614101dbc8c"><gtr:id>2b8ec340d2699a7f67d03614101dbc8c</gtr:id><gtr:otherNames>Lokireddy P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>cWDuR5yAcSo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5550F0A-FD67-46BE-AC46-EAE37FAB6BC3</gtr:id><gtr:title>New Agents to Treat Chronic Lymphocytic Leukemia.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9b99469952c8d3f6e301023ab6fd7e1"><gtr:id>b9b99469952c8d3f6e301023ab6fd7e1</gtr:id><gtr:otherNames>Walter HS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>58c798f1bb6940.08074720</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DADCB067-6CD2-4296-B4C0-B36072316D30</gtr:id><gtr:title>Erythema annulare centrifugum associated with chronic lymphocytic leukaemia.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d279036aecb05e855b478d4b2337755d"><gtr:id>d279036aecb05e855b478d4b2337755d</gtr:id><gtr:otherNames>Helbling I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>A6BB2130A21</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4D66746-0BD8-4FC9-8BBA-96965A670465</gtr:id><gtr:title>Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a805d21d2fdc8cd924744bf32f7e6da"><gtr:id>2a805d21d2fdc8cd924744bf32f7e6da</gtr:id><gtr:otherNames>Vogler M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>A9DC486FFA4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7140548A-4DE8-4A6C-AA32-E6D310684E89</gtr:id><gtr:title>Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/540f181d64473b72abd43842878e0ffe"><gtr:id>540f181d64473b72abd43842878e0ffe</gtr:id><gtr:otherNames>Ribrag V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>58c7970e59e139.97510040</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>969AB075-6015-492C-9408-8DA8F965736A</gtr:id><gtr:title>Enhancing the anti-lymphoma potential of 3,4-methylenedioxymethamphetamine ('ecstasy') through iterative chemical redesign: mechanisms and pathways to cell death.</gtr:title><gtr:parentPublicationTitle>Investigational new drugs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c758260dcbf216e3a8a858f017bdd120"><gtr:id>c758260dcbf216e3a8a858f017bdd120</gtr:id><gtr:otherNames>Wasik AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0167-6997</gtr:issn><gtr:outcomeId>HPua6vDYuAX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14340BCB-FB08-4754-BC23-77FBD59D9A65</gtr:id><gtr:title>Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df7347a522f50dd909b040deb4c45a69"><gtr:id>df7347a522f50dd909b040deb4c45a69</gtr:id><gtr:otherNames>Osterborg A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>8C3AAA114D0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>243AB0E9-61EC-4344-8243-752C67B5A05C</gtr:id><gtr:title>Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75fc246188fbc17b5b2dd2408f9e5a41"><gtr:id>75fc246188fbc17b5b2dd2408f9e5a41</gtr:id><gtr:otherNames>Catovsky D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>87C053F042B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CABB6CD-86FF-4C62-A21B-1BC9CF119AED</gtr:id><gtr:title>Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1448bee0ae56bd58fecff6db43339f5"><gtr:id>a1448bee0ae56bd58fecff6db43339f5</gtr:id><gtr:otherNames>Bellodi C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>B3643685AB4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6109606-DEDE-4EE4-B5D7-099B19C8164D</gtr:id><gtr:title>Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a805d21d2fdc8cd924744bf32f7e6da"><gtr:id>2a805d21d2fdc8cd924744bf32f7e6da</gtr:id><gtr:otherNames>Vogler M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>VJ4YdoZSBik</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>499B88A4-4A9E-4B64-8617-17DD46DD38B4</gtr:id><gtr:title>Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.</gtr:title><gtr:parentPublicationTitle>American journal of hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ff1812dd1832ef6845309062f56ed79"><gtr:id>3ff1812dd1832ef6845309062f56ed79</gtr:id><gtr:otherNames>Jardin F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0361-8609</gtr:issn><gtr:outcomeId>58c798288f6bc2.72085997</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1BE6CB78-BAF5-4729-B3CE-D341A77DBCAD</gtr:id><gtr:title>Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e80d90bf84f34160134f7d8468237c1"><gtr:id>3e80d90bf84f34160134f7d8468237c1</gtr:id><gtr:otherNames>Austen B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>3C31CD40AE6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD818558-E9C4-4CCB-BF31-A9230F1018D6</gtr:id><gtr:title>Immunoglobulin heavy chain locus chromosomal translocations in B-cell precursor acute lymphoblastic leukemia: rare clinical curios or potent genetic drivers?</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50211a37a4654b2dfd8ff8b075e17c3a"><gtr:id>50211a37a4654b2dfd8ff8b075e17c3a</gtr:id><gtr:otherNames>Dyer MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>fySMMauenid</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D45D323-7EBA-4793-ABD0-64C1576D90A8</gtr:id><gtr:title>Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fdb8ace7901e715c0cb5bc22b90faaf1"><gtr:id>fdb8ace7901e715c0cb5bc22b90faaf1</gtr:id><gtr:otherNames>Syed N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>42329149235</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7ED0E484-AADF-4A22-80B2-10A8D9532E86</gtr:id><gtr:title>E?/miR-125b transgenic mice develop lethal B-cell malignancies.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/952cbaeb3775d182c23a0d92824c1950"><gtr:id>952cbaeb3775d182c23a0d92824c1950</gtr:id><gtr:otherNames>Enomoto Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>nZHTEZAhQ6r</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBC99CF5-3A4B-44A0-8A8D-43D1136C1642</gtr:id><gtr:title>ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5c4afad9ed63e2ce14e6955cc09639a"><gtr:id>d5c4afad9ed63e2ce14e6955cc09639a</gtr:id><gtr:otherNames>Skowronska A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>b1Bukj9zSgj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3714BE4F-2AA1-480C-883F-960C04C3FAFC</gtr:id><gtr:title>Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94cee47a1a80481a7f658cdf3b5149c2"><gtr:id>94cee47a1a80481a7f658cdf3b5149c2</gtr:id><gtr:otherNames>Law PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58c796e1cc7855.31215960</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07E4CC96-6936-4E57-8EFD-D188CF957945</gtr:id><gtr:title>Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aabb4a3c08d22654d635504cdccd286f"><gtr:id>aabb4a3c08d22654d635504cdccd286f</gtr:id><gtr:otherNames>Chen Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>58c797d112e720.35840072</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CBCFA84-CE94-4BE8-B349-123D902FBAA6</gtr:id><gtr:title>Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75863d44d38390b793a438ac87b9f44b"><gtr:id>75863d44d38390b793a438ac87b9f44b</gtr:id><gtr:otherNames>Inoue S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>DACE1C2539D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BDEA87A-F5F9-49A6-BFC8-6E3F4F2E4D71</gtr:id><gtr:title>Alemtuzumab-resistant S&amp;eacute;zary syndrome responding to zanolimumab.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f096c65976e514f4d7201025e733db1c"><gtr:id>f096c65976e514f4d7201025e733db1c</gtr:id><gtr:otherNames>Alexandroff AB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>bSTXb1bBHUo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43CDDC49-8B85-4888-AA6F-186B2FDFD5A2</gtr:id><gtr:title>Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b08c3c4b77b1d4beba13cffbcdad69b8"><gtr:id>b08c3c4b77b1d4beba13cffbcdad69b8</gtr:id><gtr:otherNames>Ryan CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>58c7976c0c1711.33742887</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7486AC9-CF84-460B-9B7E-3D17C6230B63</gtr:id><gtr:title>Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/46961b169ccf4e249b20ecce7dce53fa"><gtr:id>46961b169ccf4e249b20ecce7dce53fa</gtr:id><gtr:otherNames>Grant H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>FRQTDrhSw1R</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FEDA4C95-E53C-462F-8E4F-C21B39214C41</gtr:id><gtr:title>Identification of the gene encoding cyclin E1 (CCNE1) as a novel IGH translocation partner in t(14;19)(q32;q12) in diffuse large B-cell lymphoma.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/975a5f7128d7e2300880c46017366ddd"><gtr:id>975a5f7128d7e2300880c46017366ddd</gtr:id><gtr:otherNames>Nagel I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>D81F0C4BAEB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95AEE76F-222B-4A59-8054-E84A6B0F69A9</gtr:id><gtr:title>A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01e49742b040c5a0b64ded49290b7484"><gtr:id>01e49742b040c5a0b64ded49290b7484</gtr:id><gtr:otherNames>Sellick GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>15C89C4AC21</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83FF1A35-062B-48DF-A5C5-98C1B00949DB</gtr:id><gtr:title>Gains of REL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein.</gtr:title><gtr:parentPublicationTitle>Genes, chromosomes &amp; cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c8815a9bb4c1ff740ac810e6e6f1001"><gtr:id>9c8815a9bb4c1ff740ac810e6e6f1001</gtr:id><gtr:otherNames>Weniger MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1045-2257</gtr:issn><gtr:outcomeId>5C20FF9B12C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F59DEA8-177C-45B5-B1FA-E57EB18822E9</gtr:id><gtr:title>Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL).</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54c75b15a0ae439e3822e8bcbbb54575"><gtr:id>54c75b15a0ae439e3822e8bcbbb54575</gtr:id><gtr:otherNames>Akasaka T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>0F6AC82FA06</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56CD4414-745F-4998-A94D-E4F113547BE9</gtr:id><gtr:title>A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a805d21d2fdc8cd924744bf32f7e6da"><gtr:id>2a805d21d2fdc8cd924744bf32f7e6da</gtr:id><gtr:otherNames>Vogler M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>9B4F9F406D5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6DD7A18-55C8-4BD5-8191-7CBCA105802F</gtr:id><gtr:title>Splenic infarction associated with rapidly progressive chronic lymphocytic leukemia with complex karyotype and ATM mutation.</gtr:title><gtr:parentPublicationTitle>Leukemia research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50211a37a4654b2dfd8ff8b075e17c3a"><gtr:id>50211a37a4654b2dfd8ff8b075e17c3a</gtr:id><gtr:otherNames>Dyer MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0145-2126</gtr:issn><gtr:outcomeId>hAoknE3eLtt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37310540-D5C3-4967-922C-585ED8A8A848</gtr:id><gtr:title>Obinutuzumab-induced coagulopathy in chronic lymphocytic leukaemia with trisomy 12.</gtr:title><gtr:parentPublicationTitle>Blood cancer journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9b99469952c8d3f6e301023ab6fd7e1"><gtr:id>b9b99469952c8d3f6e301023ab6fd7e1</gtr:id><gtr:otherNames>Walter HS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2044-5385</gtr:issn><gtr:outcomeId>58c79800d4ae96.25468562</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8025D417-F9E0-48F0-90BD-366BD6F4722D</gtr:id><gtr:title>Activity of thalidomide and lenalidomide in mantle cell lymphoma.</gtr:title><gtr:parentPublicationTitle>Acta haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/192c85d9cf331c24a5544b600769f0b5"><gtr:id>192c85d9cf331c24a5544b600769f0b5</gtr:id><gtr:otherNames>Richardson SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0001-5792</gtr:issn><gtr:outcomeId>5B1901027E8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4A47890-E4CB-4283-91F4-699C11A9316C</gtr:id><gtr:title>Inhibition of bortezomib-induced apoptosis by red blood cell uptake.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0bcb6b5997f145d7224f3668e8d82ec8"><gtr:id>0bcb6b5997f145d7224f3668e8d82ec8</gtr:id><gtr:otherNames>Wheat LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>76DBE767850</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>566FF557-0A71-4540-943E-B32C052999C9</gtr:id><gtr:title>Proteomic analysis of cell surface membrane proteins in leukemic cells.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/398a9184d82432ea64cdc3932cb993ea"><gtr:id>398a9184d82432ea64cdc3932cb993ea</gtr:id><gtr:otherNames>Boyd RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>67E48EA4529</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D684E3FD-CC67-4F2C-AE77-CDA31836FF21</gtr:id><gtr:title>Laparoscopic splenectomy: a personal series of 140 consecutive cases.</gtr:title><gtr:parentPublicationTitle>Annals of the Royal College of Surgeons of England</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32b50231a405fe522a59a182de164590"><gtr:id>32b50231a405fe522a59a182de164590</gtr:id><gtr:otherNames>Pattenden CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0035-8843</gtr:issn><gtr:outcomeId>eZM1fvpCKzk</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8E6FA93-353C-41F4-9279-33877D46C64B</gtr:id><gtr:title>Genetic variation in CXCR4 and risk of chronic lymphocytic leukemia.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/809050a2f2f177032cb1ea21238c8aa3"><gtr:id>809050a2f2f177032cb1ea21238c8aa3</gtr:id><gtr:otherNames>Crowther-Swanepoel D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>0C4108A5572</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6620E2AA-BFDA-40E2-85F8-3D593039B0BE</gtr:id><gtr:title>Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/809050a2f2f177032cb1ea21238c8aa3"><gtr:id>809050a2f2f177032cb1ea21238c8aa3</gtr:id><gtr:otherNames>Crowther-Swanepoel D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>VEd5rxxNphJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3AFFFC9-219A-4869-A1EB-9B8A21DDF7EF</gtr:id><gtr:title>Chromosomal translocations fusing the BCL6 gene to different partner loci are recurrent in primary central nervous system lymphoma and may be associated with aberrant somatic hypermutation or defective class switch recombination.</gtr:title><gtr:parentPublicationTitle>Journal of neuropathology and experimental neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67d16252a4270cf70ababcf9c8df3d56"><gtr:id>67d16252a4270cf70ababcf9c8df3d56</gtr:id><gtr:otherNames>Schwindt H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-3069</gtr:issn><gtr:outcomeId>F00D0634CB3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B852425-0B5B-422D-A54A-731BAA849B7C</gtr:id><gtr:title>HHV-8-unrelated primary effusion-like lymphoma associated with clonal loss of inherited chromosomally-integrated human herpesvirus-6A from the telomere of chromosome 19q.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1dd9245f344d31c5ed78e838582648b4"><gtr:id>1dd9245f344d31c5ed78e838582648b4</gtr:id><gtr:otherNames>Zhang E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>58c798bc261353.96734739</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BD814E3-37BA-405E-992F-B8792311877B</gtr:id><gtr:title>Identification of Thr29 as a critical phosphorylation site that activates the human proton channel Hvcn1 in leukocytes.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb3cb5e21de1d5af44690f56df0ac451"><gtr:id>bb3cb5e21de1d5af44690f56df0ac451</gtr:id><gtr:otherNames>Musset B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>ev4iE6VGjTN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11A02141-DA17-4311-B8EA-FA26A626E88D</gtr:id><gtr:title>GeneChip analyses point to novel pathogenetic mechanisms in mantle cell lymphoma.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1391da15d211c6f2b3026d7511da025f"><gtr:id>1391da15d211c6f2b3026d7511da025f</gtr:id><gtr:otherNames>Vater I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>73786B9BA5D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD1989ED-825E-41F7-917F-632339E86BB2</gtr:id><gtr:title>Enforced expression of MIR142, a target of chromosome translocation in human B-cell tumors, results in B-cell depletion.</gtr:title><gtr:parentPublicationTitle>International journal of hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b06cbeb76d0a2298586731b8644a456"><gtr:id>5b06cbeb76d0a2298586731b8644a456</gtr:id><gtr:otherNames>Kuriyama K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0925-5710</gtr:issn><gtr:outcomeId>5aa41ad79e9e39.04545293</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B2CBB0B-A1D1-4475-A175-999AEC78018D</gtr:id><gtr:title>A comprehensive genetic and histopathologic analysis identifies two subgroups of B-cell malignancies carrying a t(14;19)(q32;q13) or variant BCL3-translocation.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0c4d8ce8fa41f25d5517860ecd2f946"><gtr:id>a0c4d8ce8fa41f25d5517860ecd2f946</gtr:id><gtr:otherNames>Mart?n-Subero JI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>6C50A5983A1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5377077-A9A7-421B-893E-A542EC75C0F3</gtr:id><gtr:title>A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/29e1d6bc37a5ec17e536c4bf28bf43bb"><gtr:id>29e1d6bc37a5ec17e536c4bf28bf43bb</gtr:id><gtr:otherNames>Best OG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>F0E2FD56D94</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7368825-723D-4F35-9BC8-F52F97A382E2</gtr:id><gtr:title>Gains of the proto-oncogene BCL11A and nuclear accumulation of BCL11A(XL) protein are frequent in primary mediastinal B-cell lymphoma.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c8815a9bb4c1ff740ac810e6e6f1001"><gtr:id>9c8815a9bb4c1ff740ac810e6e6f1001</gtr:id><gtr:otherNames>Weniger MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>953DCB0CD02</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD5D6B68-BF70-4BA9-BBA3-20093E5F2FAC</gtr:id><gtr:title>Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c11711d1d0eb5e5a8f750499cfcc557d"><gtr:id>c11711d1d0eb5e5a8f750499cfcc557d</gtr:id><gtr:otherNames>Parker H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>58c7979ee130e9.65715217</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26B92271-F71D-4709-824D-4EDC2FB48EFB</gtr:id><gtr:title>HVCN1 modulates BCR signal strength via regulation of BCR-dependent generation of reactive oxygen species.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f84a595d1ec65fe050e4f11ea28f208f"><gtr:id>f84a595d1ec65fe050e4f11ea28f208f</gtr:id><gtr:otherNames>Capasso M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>pgP6a5eTvH6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA79DC58-BD94-4CA4-824E-1AC9B83FC7D5</gtr:id><gtr:title>pH regulation and beyond: unanticipated functions for the voltage-gated proton channel, HVCN1.</gtr:title><gtr:parentPublicationTitle>Trends in cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f84a595d1ec65fe050e4f11ea28f208f"><gtr:id>f84a595d1ec65fe050e4f11ea28f208f</gtr:id><gtr:otherNames>Capasso M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0962-8924</gtr:issn><gtr:outcomeId>FNdr57FKtPb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9033D96-B56B-4EB9-9E22-268A7B2934FF</gtr:id><gtr:title>The impact of follicular lymphoma on health-related quality of life.</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/957a9a0d83d4bacc713ab77a0b37c804"><gtr:id>957a9a0d83d4bacc713ab77a0b37c804</gtr:id><gtr:otherNames>Pettengell R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn><gtr:outcomeId>15D8404310F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A890E953-B7B9-4F73-81F5-0E3ED01C5A09</gtr:id><gtr:title>BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a805d21d2fdc8cd924744bf32f7e6da"><gtr:id>2a805d21d2fdc8cd924744bf32f7e6da</gtr:id><gtr:otherNames>Vogler M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>ba4sYnYiKc1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14CE71F5-2C76-456F-A90F-AA08F9DF84B0</gtr:id><gtr:title>Novel markers of normal and neoplastic human plasmacytoid dendritic cells.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1110bf9c5ff19316730d11cceff988e"><gtr:id>a1110bf9c5ff19316730d11cceff988e</gtr:id><gtr:otherNames>Marafioti T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>9D4924CB541</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC795EDA-0866-4BCB-BAF4-55750B06FB65</gtr:id><gtr:title>Germ line mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/680cc745cb27d99e25e49bb7b5349b1e"><gtr:id>680cc745cb27d99e25e49bb7b5349b1e</gtr:id><gtr:otherNames>Speedy HE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>58c79971505054.25209389</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96D602D7-1EA8-4AA9-A88B-6DFCDF91FB04</gtr:id><gtr:title>Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8bc975367333bca90b1f969d8be308c"><gtr:id>a8bc975367333bca90b1f969d8be308c</gtr:id><gtr:otherNames>Navarro A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>5aa41b94073597.03112688</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63BB6184-58EB-4B38-A32F-D89EEAC31CB4</gtr:id><gtr:title>CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL.</gtr:title><gtr:parentPublicationTitle>Leukemia research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e6a552e5d5bb32456180c5d8cc7ff7e"><gtr:id>2e6a552e5d5bb32456180c5d8cc7ff7e</gtr:id><gtr:otherNames>Majid A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0145-2126</gtr:issn><gtr:outcomeId>V2dD2zTQ4Ym</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22B26790-8228-4526-B1C7-7712242F72C9</gtr:id><gtr:title>A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/29e1d6bc37a5ec17e536c4bf28bf43bb"><gtr:id>29e1d6bc37a5ec17e536c4bf28bf43bb</gtr:id><gtr:otherNames>Best OG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>660B99CD9F6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D301029A-6585-4FD0-A521-F09E4ABE2E5A</gtr:id><gtr:title>Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d77dd2c99140e6514fe822714ca22dc"><gtr:id>4d77dd2c99140e6514fe822714ca22dc</gtr:id><gtr:otherNames>Melzner I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>FB5AC99C2F1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31610E38-5006-4DDC-AB57-5F9747AEBC87</gtr:id><gtr:title>Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75863d44d38390b793a438ac87b9f44b"><gtr:id>75863d44d38390b793a438ac87b9f44b</gtr:id><gtr:otherNames>Inoue S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>37775396DFB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A194829F-1529-4E55-A2AA-536788B15741</gtr:id><gtr:title>A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/64322fa4e407100bc0dc4ac82f9b9ee2"><gtr:id>64322fa4e407100bc0dc4ac82f9b9ee2</gtr:id><gtr:otherNames>Burton C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>F9B275ADA7D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF63368A-7370-4B39-B812-CC33068760F3</gtr:id><gtr:title>Functional studies of BCL11A: characterization of the conserved BCL11A-XL splice variant and its interaction with BCL6 in nuclear paraspeckles of germinal center B cells.</gtr:title><gtr:parentPublicationTitle>Molecular cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9b8f6134f2dda035c13e759d60eac1e"><gtr:id>b9b8f6134f2dda035c13e759d60eac1e</gtr:id><gtr:otherNames>Liu H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1476-4598</gtr:issn><gtr:outcomeId>C4B181D11E7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7168888B-7464-4AA4-BDB4-29419A5BF31F</gtr:id><gtr:title>A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c62ccabfac3fa03b5d3cbeecec65a05d"><gtr:id>c62ccabfac3fa03b5d3cbeecec65a05d</gtr:id><gtr:otherNames>Martin-Subero JI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>C630267A7E9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DFF253C-6264-4258-B478-B7D2F8FB0A88</gtr:id><gtr:title>Peripheral T-cell non-Hodgkin's lymphoma NOS: naming of parts.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50211a37a4654b2dfd8ff8b075e17c3a"><gtr:id>50211a37a4654b2dfd8ff8b075e17c3a</gtr:id><gtr:otherNames>Dyer MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>58AE22FA8E1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ACE4BF9F-0E22-4258-B5FE-C0B63EAF36A9</gtr:id><gtr:title>t(6;14)(p22;q32): a new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL).</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c8b2715d1c16f9b9d1f3591c107b062f"><gtr:id>c8b2715d1c16f9b9d1f3591c107b062f</gtr:id><gtr:otherNames>Russell LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>ED49EBC2539</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E6C5141-640F-45BB-987D-362ECC4F1EF6</gtr:id><gtr:title>Upregulation of TRAIL-R2 is not involved in HDACi mediated sensitization to TRAIL-induced apoptosis.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75863d44d38390b793a438ac87b9f44b"><gtr:id>75863d44d38390b793a438ac87b9f44b</gtr:id><gtr:otherNames>Inoue S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>165E57525D6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>29D68C7B-0B3B-4229-81E4-34C742C06A8F</gtr:id><gtr:title>Fine-scale mapping of the 6p25.3 chronic lymphocytic leukaemia susceptibility locus.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/809050a2f2f177032cb1ea21238c8aa3"><gtr:id>809050a2f2f177032cb1ea21238c8aa3</gtr:id><gtr:otherNames>Crowther-Swanepoel D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>n7K2GiZ9H4v</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>36AFF459-C2B7-4C4D-8E58-3CE727B4B382</gtr:id><gtr:title>Male preponderance in chronic lymphocytic leukemia utilizing IGHV 1-69.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6358507b9f789e3584d545318eda4ffe"><gtr:id>6358507b9f789e3584d545318eda4ffe</gtr:id><gtr:otherNames>Walewska R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>23EBFE201E7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0851D4F7-4120-4027-A38A-D15550820354</gtr:id><gtr:title>Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6bf73897bea971b0d86bfd7f2577f8fe"><gtr:id>6bf73897bea971b0d86bfd7f2577f8fe</gtr:id><gtr:otherNames>Wierda WG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>q8TUWrLXP9B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08E3114C-DF08-4E16-9DB4-BC6565645188</gtr:id><gtr:title>Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLL.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/809050a2f2f177032cb1ea21238c8aa3"><gtr:id>809050a2f2f177032cb1ea21238c8aa3</gtr:id><gtr:otherNames>Crowther-Swanepoel D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>02F4D7510EA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2703EB1D-3AC6-4D60-AB52-B7EBEC6E013E</gtr:id><gtr:title>Eosinophilic cellulitis as a presenting feature of chronic eosinophilic leukaemia, secondary to a deletion on chromosome 4q12 creating the FIP1L1-PDGFRA fusion gene.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/37396c2e750e17d5ad3b5b058a4f7b9c"><gtr:id>37396c2e750e17d5ad3b5b058a4f7b9c</gtr:id><gtr:otherNames>Davis RF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>4B492CE2801</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A90366B2-840F-40FC-BA1C-0651E791848C</gtr:id><gtr:title>Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a805d21d2fdc8cd924744bf32f7e6da"><gtr:id>2a805d21d2fdc8cd924744bf32f7e6da</gtr:id><gtr:otherNames>Vogler M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>5aa41bc455ba69.33448153</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U132670597</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>